
Claims:

1. A compound represented by Formula I:



(I)

or a pharmaceutically acceptable salt thereof; wherein:

R^1 is phenyl substituted by (i) cyano and m occurrences of R^4, and (ii) C_{1-4} alkoxyl or C_{1-4} haloalkoxyl;

R^2 represents independently for each occurrence C_{1-4} alkyl;

R^3 is hydrogen or C_{1-4} alkyl;


R^4 is C_{1-4} alkyl;

R^5 represents independently for each occurrence C_{1-4} alkyl or halogen;


A^1 is a pyrimidinylene, pyridazinylene, pyrazinylene, pyridinylene, or phenylene, each of which is substituted with n occurrences of R^5;

L is a linker; and

A^2 is one of the following:



or



;

B^1 is (i) cyclobutylene substituted by 1, 2, 3, or 4 occurrences of R^2 or (ii) cyclohexylene substituted by 0, 1, or 2 occurrences of R^2;

R^{1A} is C_{1-4} alkyl or C_{3-4} cycloalkyl;

R^{2A} represents independently for each occurrence C_{1-4} alkyl or C_{3-4} cycloalkyl;

R^{3A} is hydrogen, halo, C_{1-4} alkyl, C_{1-4} haloalkyl, or C_{1-4} alkoxyl;

R^{4A} is -(C_{0-6} alkylene)-(5-6 membered heteroaryl containing 1, 2, or 3 heteroatoms independently selected from nitrogen, oxygen, and sulfur), -(C_{1-6} alkylene)-$C(O)N(R^{5A})(R^{6A})$, -(C_{1-6} alkylene)-$N(R^{5A})C(O)R^{7A}$, -(C_{1-6} alkylene)-CO_2R^{7A}, -(C_{1-6}

alkylene)-OC(O)R^{7A}, -(C_{1-6} alkylene)-cyano, -(C_{1-6} alkylene)-O-(C_{1-6} alkyl), C_{1-6} alkyl, C_{3-6} cycloalkyl, or hydrogen; or R^{4A} and R^{10A} taken together with the carbon atom to which they are attached form a C_{3-5} saturated carbocyclic ring;


R^{5A} and R^{6A} are independently hydrogen, C_{1-6} alkyl, or C_{3-6} cycloalkyl; or R^{5A} and R^{6A} are taken together with the nitrogen atom to which they are attached to form a 3-7 membered ring containing 1 nitrogen atom;

R^{7A} is C_{1-6} alkyl, -(C_{1-6} alkylene)-(C_{3-6} cycloalkyl), or C_{3-6} cycloalkyl;

R^{10A} is hydrogen or C_{1-4} alkyl; and


m, n, and p are independently 0, 1, or 2.

2. The compound of claim 1, wherein the compound is a compound of Formula Ie or a pharmaceutically acceptable salt thereof:




(Ie).



3. The compound of claim 1, wherein the compound is a compound of Formula Io or Ip, or a pharmaceutically acceptable salt thereof:




(Io)




(Ip).





4. The compound of any one of claims 1-3, wherein A^1 is  or , where ** is the point of attachment to L.

5. The compound of any one of claims 1-4, wherein A^2 is .

6. The compound of any one of claims 1-5, wherein R^{4A} is -(C_{1-2} alkylene)-(oxazolyl) or methyl.

7. The compound of any one of claims 1-6, wherein R^{1A} is methyl, R^{2A} is methyl, and p is 2.

8. The compound of any one of claims 1-4, wherein A^2 is .


9. The compound of any one of claims 1-4, wherein A^2 is , , , or .

10. The compound of any one of claims 1-9, wherein L is a bivalent, saturated or unsaturated, straight or branched C_{1-60} hydrocarbon chain, wherein 0-20 methylene units of the hydrocarbon are independently replaced with -O-, -S-, -N(H)-, -N(C_{1-6} alkyl)-, -OC(O)-, -C(O)O-, -S(O)-, -$S(O)_2$-, -N(H)$S(O)_2$-, -N(C_{1-6} alkyl)$S(O)_2$-, -$S(O)_2$N(H)-, -$S(O)_2$N(C_{1-6} alkyl)-, -N(H)C(O)-, -N(C_{1-6} alkyl)C(O)-, -C(O)N(H)-, -C(O)N(C_{1-6} alkyl)-, -OC(O)N(H)-, -OC(O)N(C_{1-6} alkyl)-, -N(H)C(O)O-, -N(C_{1-6} alkyl)C(O)O-, -N(optionally substituted 3-10

membered carbocyclyl)-, optionally substituted 3-10 membered carbocyclyl, or optionally substituted 3-10 membered heterocyclyl containing 1, 2, 3, or 4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.


11. The compound of any one of claims 1-9, wherein L is -(7-11 membered spirocyclic or fused bicyclic saturated heterocyclic ring containing 1, 2, or 3 heteroatoms selected from nitrogen and oxygen)-X^1-***, wherein X^1 is C_{0-4} alkylene, C_{2-4} alkynylene, or O, wherein *** is the point of attachment to A^2.

12. The compound of any one of claims 1-9, wherein L is one of the following:




wherein *** is the point of attachment to A^2.


13. The compound of claim 1, wherein the compound is represented by Formula It, Iu, Iv, or Iw, or a pharmaceutically acceptable salt thereof:




(It)



(Iu)



(Iv)



(Iw)

wherein


L is one of the following:

(i) -(7-11 membered spirocyclic or fused bicyclic saturated heterocyclic ring containing 1, 2, or 3 heteroatoms independently selected from nitrogen and oxygen)-O-***, wherein *** is the point of attachment to the phenylene group in said formula;


(ii) a 7-11 membered spirocyclic or fused bicyclic saturated heterocyclic ring containing 1, 2, or 3 heteroatoms independently selected from nitrogen and oxygen; or (iii) -(7-11 membered spirocyclic saturated heterocyclic ring containing 1 or 2 heteroatoms selected from nitrogen)-(C_{2-4} alkynylene)-***, wherein *** is the point of attachment to the phenylene group in said formula; and

t is 0 or 1.


14. The compound of claim 1, wherein the compound is represented by Formula Ix, Iy, Iz, or Iaa, or a pharmaceutically acceptable salt thereof:




(Ix)



(Iy)



(Iz)



(Iaa)

wherein:

R^{20} is methyl, ethyl, $-CH_2-O-CH_3$, or $-(CH_2)_2-O-CH_3$;

L is one of the following:

(i) -(7-11 membered spirocyclic or fused bicyclic saturated heterocyclic ring containing 1, 2, or 3 heteroatoms independently selected from nitrogen and oxygen)-O-***, wherein *** is the point of attachment to the phenylene group in said formula;

(ii) a 7-11 membered spirocyclic or fused bicyclic saturated heterocyclic ring containing 1, 2, or 3 heteroatoms independently selected from nitrogen and oxygen; or

(iii) -(7-11 membered spirocyclic saturated heterocyclic ring containing 1 or 2 heteroatoms selected from nitrogen)-(C_{2-4} alkynylene)-***, wherein *** is the point of attachment to the phenylene group in said formula; and


t is 0 or 1.

15. The compound of claim 13 or 14, wherein L is a -(7-11 membered spirocyclic or fused bicyclic saturated heterocyclic ring containing 1, 2, or 3 heteroatoms independently

selected from nitrogen and oxygen)-O-***, wherein *** is the point of attachment to the phenylene group in said formula.


16. The compound of claim 13 or 14, wherein L is -(7-11 membered spirocyclic saturated heterocyclic ring containing 1 or 2 heteroatoms selected from nitrogen)-(C_{2-4} alkynylene)-***, wherein *** is the point of attachment to the phenylene group in said formula.

17. The compound of claim 13 or 14, wherein L is one of the following:




wherein *** is the point of attachment to the phenylene group in said formula.

18. The compound of claim 13, wherein the compound is represented by Formula Iab or a pharmaceutically acceptable salt thereof:




(Iab).

19. The compound of claim 13, wherein the compound is represented by Formula Iac or a pharmaceutically acceptable salt thereof:



(Iac).


20. The compound of claim 13, wherein the compound is represented by Formula Iad:



(Iad).

21. The compound of claim 1, wherein the compound is a compound in Table 1 or 2, or a pharmaceutically acceptable salt thereof.

22. The compound of claim 20, wherein the compound is a crystalline compound of Formula II-5:



(II-5).

23. The compound of claim 22, wherein the compound exhibits an X-ray powder diffraction pattern comprising peaks at the following diffraction angles (2θ): 13.1 ± 0.2, 17.6 ± 0.2, 18.3 ± 0.2, 18.7 ± 0.2, 19.5 ± 0.2, 23.8 ± 0.2, and 25.6 ± 0.2.

24. The compound of claim 23, wherein the X-ray powder diffraction pattern further comprises peaks at the following diffraction angles (2θ): 8.1 ± 0.2, 9.9 ± 0.2, 10.5 ± 0.2, 15.8 ± 0.2, 19.8 ± 0.2, and 25.3 ± 0.2.

25. The compound of claim 23 or 24, wherein the relative intensity of the peak at said diffraction angles (2θ) is at least 20%.

26. The compound of claim 22, characterized by the following X-ray powder diffraction pattern expressed in terms of diffraction angle 2θ, inter-planar distances d, and relative intensity (expressed as a percentage with respect to the most intense peak):

Angle [2θ]	**d-spacing [Å]**	**Relative Intensity [%]**
8.1	11.0	28
8.3	10.6	13
8.6	10.2	22
9.5	9.3	8
9.9	8.9	34
10.5	8.4	31
11.7	7.6	9
12.1	7.3	8
13.1	6.8	81
13.5	6.5	9
15.5	5.7	10
15.8	5.6	28
16.1	5.5	14
16.6	5.3	9
17.6	5.0	39
18.0	4.9	14
18.3	4.9	38
18.7	4.7	37
19.5	4.5	100
19.8	4.5	37
20.4	4.4	11
21.6	4.1	22
22.7	3.9	5
23.3	3.8	9
23.5	3.8	21
23.8	3.7	56

Angle [2θ]	d-spacing [Å]	Relative Intensity [%]
24.3	3.7	22
25.1	3.5	20
25.3	3.5	30
25.6	3.5	64
26.2	3.4	7
27.0	3.3	6
27.5	3.2	7
28.8	3.1	6
31.9	2.8	6
33.1	2.7	5
33.7	2.7	8


.

27. The compound of any one of claims 22-26, wherein the compound has a melting point onset as determined by differential scanning calorimetry in the range of from about 180 degrees Celsius to about 200 degrees Celsius, optionally wherein the compound has a melting point onset as determined by differential scanning calorimetry at about 192 degrees Celsius.

28. The compound of any one of claims 22-27, wherein the compound has a purity of greater than 99% by weight.

29. A pharmaceutical composition comprising a compound of any one of claims 1-28 and a pharmaceutically acceptable carrier.

30. The pharmaceutical composition of claim 29, wherein the compound is represented by Formula Iad:




(Iad).

31. Use of a compound of any one of claims 1-28 in the manufacture of a medicament for treating cancer, wherein the cancer is ovarian cancer, uterine cancer, endometrial cancer,

cervical cancer, prostate cancer, testicular cancer, breast cancer, brain cancer, lung cancer, oral cancer, esophageal cancer, head and neck cancer, stomach cancer, colon cancer, rectal cancer, skin cancer, sebaceous gland carcinoma, bile duct cancer, gallbladder cancer, liver cancer, pancreatic cancer, bladder cancer, urinary tract cancer, kidney cancer, eye cancer, thyroid cancer, lymphoma, or leukemia.

32. The use of claim 31, wherein the cancer is prostate cancer.

33. The use of claim 31 or 32, wherein the compound is represented by Formula Iad:



(Iad).